Cue chalks up phase 2 hives win for Xolair challenger
A midstage study of Cue Biopharma's CUE-221 hit its primary endpoint in chronic spontaneous urticaria, emboldening the biotech to move the would-be Xolair challenger into a phase 2b/3 trial.
Cue Biopharma
NASDAQ: CUE $25.39 USD
Clinical-stage biopharmaceutical company developing Immuno-STAT biologics designed to selectively engage disease-relevant T cells for cancer and autoimmune disease; its CUE-221 candidate for chronic spontaneous urticaria hit its Phase 2 primary endpoint in September 2026.
Company Info
Sector:Biologics / Immunotherapy
Headquarters:Boston, Massachusetts, USA
Founded:2015
Website:www.cuebiopharma.com/
Upcoming Milestones & Key Dates
2026 Q4
Clinical
Phase 2b/3 trial start for CUE-221 in chronic spontaneous urticaria
Clinical Development Pipeline
CUE-221
Target: IL-2-based Immuno-STAT immunomodulatorCUE-401
Target: IL-2 / Immuno-STATRecent News
Leadership Team
Pasha Sarraf
Chairman of the Board
Steven Almo
Co-Founder and Chair of Scientific Advisory Board
Rodolfo J. Chaparro
Co-Founder